Showing results (11-20 of 38) with videos related to
Sort By:
Pageof 4
Translational Oncology|June 3, 2020
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant ChemotherapyClaudia Omarini, Stefania Bettelli, Samantha Manfredini, et al.BMC Cancer|May 15, 2020
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trialsClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.Journal of Clinical Pathology|March 6, 2012
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysisMaria Vittoria Dieci, Elena Barbieri, Stefania Bettelli, et al.Breast Cancer (Tokyo, Japan)|December 20, 2018
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapyGiorgia Guaitoli, Federico Piacentini, Claudia Omarini, et al.BMC Cancer|June 7, 2022
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysisClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.Clinical Breast Cancer|August 21, 2019
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysisAngela Toss, Marta Venturelli, Isabella Sperduti, et al.Biomedicines|January 21, 2023
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesKrisida Cerma, Federico Piacentini, Luca Moscetti, et al.Clinical Breast Cancer|September 29, 2023
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-AnalysisRaffaella D'Onofrio, Isabella Sperduti, Federico Piacentini, et al.Cancers|October 13, 2021
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the LiteratureChrystel Isca, Federico Piacentini, Ilenia Mastrolia, et al.Clinical Breast Cancer|July 28, 2023
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World SettingRaffaella D'Onofrio, Claudia Omarini, Angela Toss, et al.Pageof 4